Sotorasib for advanced non-small cell lung cancer
Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France
Hi everyone, I’m Fabrice Barlesi from the Gustave Roussy cancer campus in Paris and ex-Marseilles University. I would like to summarise the data presented during ESMO 2020 regarding the AMG-510, sotorasib, which is a specific KRAS G12C inhibitor. During the meeting the updated results of the phase I study were presented. As you know, this study was dedicated to advanced non-small cell lung cancer patients with a G12C mutation, KRAS mutation, with different levels of dosage for the drug and a summary of the extension phase.
The drug was quite well tolerated. When we look at the treatment related adverse events, 60% of the patients presented with at least treatment related adverse events with 18.6% presenting with a grade 3 or more treatment related adverse event.
Very importantly, the efficacy was updated during this presentation. The overall response rate in this heavily pre-treated patient population was 35.3% which has to be put in line with the expected 12-15% response rate with docetaxel which was the standard of care up until now. Then these updated results make sotorasib a potential new future standard of care in this patient population and we look to the advance and the results of the phase III ongoing trial.